Cancer Currents: An NCI Cancer Research Blog
A blog featuring news and research updates from the National Cancer Institute. Learn more about Cancer Currents.
-
NCI’s Steven Rosenberg Wins Service to America MedalThe Partnership for Public Service has awarded Steven A. Rosenberg, M.D., of NCI's Center for Cancer Research, with its highest 2015 Samuel J. Heyman Service to America Medal, or Sammie.
-
Persistence of Genetic Mutations after Chemotherapy Linked to Poor Outcomes in Some Patients with AMLThe persistence of genetic mutations in some patients with acute myeloid leukemia may allow physicians to better classify their risk of recurrence.
-
"Fine Tuning" Engineered T Cells May Extend Immunotherapy Approach to More Cancer TypesEngineering immune cells to have a decreased affinity for their targets on cancer cells may not weaken their efficacy but may reduce the risk of side effects.
-
Cancer Trends: Influencing Care and Research PrioritiesMany of the trends being seen in cancer are changing how we view cancer and how we address it, from prompting research to identify the underlying causes of cancers increasing in incidence to informing research on treatment and prevention.
-
CPTAC, the Complementary Sibling of TCGA: An Interview with Dr. Henry Rodriguez about NCI’s Proteomics ProgramDr. Henry Rodriguez explains the goals and future directions of CPTAC, a collaborative consortium of institutions and investigators who study cancer proteomics.
-
For Some Children with Cancer, Genomic Information May Help Guide Treatment DecisionsGenomic methods, such as DNA sequencing, may help doctors manage the treatment of children and young adults with cancer.
-
NCI Releases Budget Proposal for Fiscal Year 2017The NCI Annual Plan and Budget Proposal for Fiscal Year 2017 provides an overview of NCI’s priorities and key initiatives and the institute’s funding request.
-
FDA Approves Rolapitant to Prevent Nausea and Vomiting from ChemotherapyThe FDA has approved rolapitant to prevent chemotherapy-induced nausea and vomiting.
-
NCI Initiative to Speed Development of Childhood Cancer TherapiesNCI has awarded grants to five research teams to participate in its Pediatric Preclinical Testing Consortium, which is intended to help to prioritize which agents to pursue in pediatric clinical trials.
-
Intraperitoneal Chemotherapy in Advanced Ovarian Cancer Improves Survival, But Is UnderusedUse of intraperitoneal chemotherapy, along with intravenous chemotherapy, improves survival in some women with advanced ovarian cancer, but its use in clinical practice has been limited, according to a new study.
-
FDA Approves Sonidegib for Some Patients with Advanced Basal Cell CarcinomaThe FDA has approved sonidegib for the treatment of patients with locally advanced basal cell carcinoma.
-
Cancer Risk in Childhood Cancer Survivors Continues for DecadesSurvivors of childhood cancer have an elevated risk of developing second, distinct cancers into their forties and beyond, according to a new study.
-
Overdiagnosis of Cancer: Bringing an Important Problem into FocusExperts are convening for a conference on the dilemmas posed by overdiagnosis in many types of diseases. Overdiagnosis is generally defined as the diagnosis of a disease or condition that is unlikely to ever cause harm.
-
Risk of Breast Cancer Death is Low After a Diagnosis of Ductal Carcinoma in SituWomen who are diagnosed with a condition called ductal carcinoma in situ generally have a low risk of dying from breast cancer, a new study has found.
-
FDA Approves Expanded Indication for Carfilzomib in Patients with Multiple MyelomaThe FDA has approved carfilzomib in combination with other anticancer drugs to treat patients with relapsed multiple myeloma.
-
With FDA Approval, Gefitinib Returns to U.S. Market for Some Patients with Lung CancerThe FDA last month approved gefitinib (Iressa) for the treatment of some patients with lung cancer, marking the drug’s return to the U.S. market after an earlier withdrawal.
-
Gene Therapy Approach for Ovarian Cancer Shows Encouraging Signs in Animal ModelA single injection of a gene therapy viral vector inhibited tumor growth of some mouse tumors derived from patients with recurrent ovarian cancer.
-
Too Few Patients with Cancer Communicate Preferences for End-of-Life CareMany patients with cancer and their physicians are not communicating about the patients’ preferences for end-of-life medical care, a new study suggests.
-
NCI-Designated Cancer Centers Expand, Four Awarded Comprehensive DesignationIn July 2015, the NCI’s cancer centers program expanded by adding a new institution and awarding the comprehensive designation to four existing NCI-designated cancer centers.
-
What’s New Online from NCI?NCI periodically provides updates on new websites and other online content of interest to the cancer community.